Entry Point Capital, LLC Acadia Pharmaceuticals Inc Transaction History
Entry Point Capital, LLC
- $171 Million
- Q3 2024
A detailed history of Entry Point Capital, LLC transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Entry Point Capital, LLC holds 10,970 shares of ACAD stock, worth $181,443. This represents 0.1% of its overall portfolio holdings.
Number of Shares
10,970
Previous 7,426
47.72%
Holding current value
$181,443
Previous $121 Million
99.86%
% of portfolio
0.1%
Previous 0.18%
Shares
4 transactions
Others Institutions Holding ACAD
# of Institutions
280Shares Held
156MCall Options Held
901KPut Options Held
314K-
Baker Bros. Advisors LP New York, NY42.9MShares$709 Million7.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.8MShares$229 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY13.7MShares$227 Million3.36% of portfolio
-
Black Rock Inc. New York, NY12.1MShares$200 Million0.0% of portfolio
-
State Street Corp Boston, MA5.97MShares$98.8 Million0.0% of portfolio
About ACADIA PHARMACEUTICALS INC
- Ticker ACAD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 161,843,008
- Market Cap $2.68B
- Description
- ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...